Oral Answers to Questions

Debate between Kirsten Oswald and Sajid Javid

Tuesday 1st March 2022 Commons Chamber

[Sajid Javid]

I once again express my condolences to my right hon. Friend for his loss. He is absolutely right to raise this issue and the need for more research. That is one of the reasons why, back in 2018, we announced £40 million of extra research funding over the next five years. I can tell him that some £9 million of that has already been committed to 10 projects. In addition, the Tessa Jowell Brain Matrix is an exciting new trials platform that will give people with brain cancer access to trials of treatments that are best suited for their individual tumours.

[Kirsten Oswald (East Renfrewshire) (SNP)]

T9. According to the Royal College of Obstetricians and Gynaecologists, less than 3% of medical research funding in the UK is focused on women-specific diseases such as endometriosis and polycystic ovary syndrome. They are serious conditions, but too little is known about them and we do not hear enough about them, especially polycystic ovary syndrome. The failure to increase research funding is holding back women’s outcomes and experiences. What are the UK Government doing to increase the priority given to research funding for both those conditions?

Covid-19 Update

Debate between Kirsten Oswald and Sajid Javid

Tuesday 9th November 2021 Commons Chamber

[Kirsten Oswald (East Renfrewshire) (SNP)]

I thank the Secretary of State for setting out his thinking today. The Government said in the Budget that they planned to invest responsibly. Does he believe that it was responsible to cancel a multimillion-pound contract to supply a covid vaccine that phase 3 trials show may be more effective than the Oxford vaccine, threatening hundreds of jobs in Livingston for no apparent good reason? Will he consider rethinking that unfortunate decision?

[Sajid Javid]

I know the case to which the hon. Lady is referring. We are clear in our decision, which was made for all the right reasons. I hope that she will understand that I am not at liberty at this point to share those reasons, due to commercial and legal sensitivities, but I assure her that there is absolutely no point in revisiting that decision.